Market news

Detailed price information for Azenta Inc (AZTA-Q) from The Globe and Mail including charting and trades.

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta (NASDAQ:AZTA) and its peers.

Detailed price information for Azenta Inc (AZTA-Q) from The Globe and Mail including charting and trades.

Azenta (AZTA) said Friday it received full repayment, ahead of maturity, of a $35 million secured ve

Check out the companies making headlines yesterday:

Detailed price information for Azenta Inc (AZTA-Q) from The Globe and Mail including charting and trades.

Shares of life sciences company Azenta (NASDAQ:AZTA) fell 9.1% in the afternoon session after the company announced, in a regulatory filing, that President and CEO John Marotta resigned from his executive roles and board seat, with current director Dr. Martin Madaus appointed as interim President and CEO.

Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company") today announced that current member of the Board of Directors (the "Board") Dr. Martin Madaus has been appointed interim President and CEO, and that John Marotta has resigned as an executive officer and director of the Company.

Detailed price information for Azenta Inc (AZTA-Q) from The Globe and Mail including charting and trades.

AZTA went down for a long time, resulting in a multi-year low in May 2026, but the stock has rallied higher since then.

Azenta’s second quarter showed strong momentum, with results surpassing Wall Street’s expectations for both revenue and earnings. Management attributed this outperformance to robust growth in its biorepositories and consumables and instruments (C&I) segments, which are recurring revenue businesses, alongside improved execution in Multiomics, particularly in Europe and China. CEO John Marotta highlighted, “Revenue exceeded our outlook, profitability improved sequentially and Multiomics delivered

Detailed price information for Azenta Inc (AZTA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Azenta Inc (AZTA-Q) from The Globe and Mail including charting and trades.

The 5 Most Interesting Analyst Questions From Azenta’s Q2 Earnings Call

Detailed price information for Azenta Inc (AZTA-Q) from The Globe and Mail including charting and trades.

Strong multi-omics performance in Europe and China offsets capital equipment softness, while company completes B Medical divestiture and boosts shareholder returns.

Azenta (NASDAQ:AZTA) reported third-quarter fiscal 2026 revenue that exceeded its outlook, as growth in recurring-revenue businesses and improved Multiomics performance helped offset continued unevenness in capital equipment markets. Total revenue was $161 million, up 12% on a reported basis and 9%

Moby summary of Azenta, Inc.'s Q3 2026 earnings call

Life sciences company Azenta (NASDAQ:AZTA) announced better-than-expected revenue in Q2 CY2026, with sales up 12% year on year to $161.2 million. Its non-GAAP profit of $0.16 per share was 60% above analysts’ consensus estimates.

Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2026.

Life sciences company Azenta (NASDAQ:AZTA) will be reporting results this Tuesday after the bell. Here’s what investors should know.

Detailed price information for Azenta Inc (AZTA-Q) from The Globe and Mail including charting and trades.

Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2026 earnings which ended on June 30, 2026, on Tuesday, August 4, 2026, after the market closes.

Detailed price information for Azenta Inc (AZTA-Q) from The Globe and Mail including charting and trades.

Azenta, Inc. (Nasdaq: AZTA) today announced the completion of the previously disclosed sale of its B Medical Systems business to Thelema S.à r.l.